Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research

Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis

Steven T. Bird, Abraham G. Hartzema, James M. Brophy, Mahyar Etminan and Joseph A.C. Delaney
CMAJ February 05, 2013 185 (2) E115-E120; DOI: https://doi.org/10.1503/cmaj.120677
Steven T. Bird
Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, Fla.; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; and the Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bird.steven@gmail.com
Abraham G. Hartzema
Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, Fla.; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; and the Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James M. Brophy
Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, Fla.; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; and the Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mahyar Etminan
Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, Fla.; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; and the Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph A.C. Delaney
Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, Fla.; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; and the Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading
Submit a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
References
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Minimum 7 characters.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'. Minimum 12 characters.
Your organization, institution's or residential address.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

  • the indication for the birth control pill (BCP)
    Robert W. Shepherd
    Posted on: 15 February 2013
  • PCOS- at higher risk for thromboembolism
    dhastagir s Sheriff
    Posted on: 12 February 2013
  • Posted on: (15 February 2013)
    Page navigation anchor for the indication for the birth control pill (BCP)
    the indication for the birth control pill (BCP)
    • Robert W. Shepherd, physician

    Paragraph 2 of the article begins, "Combined oral contraceptives are the mainstay treatment for PCOS." According to the 2009 Compendium of Pharmaceuticals and Specialities, estrogen-progestin birth control pills are indicated for contraception control and for the prevention of pregnancy. PCOS is not an approved indication for the BCP. Bird et al found a 2 fold increased risk of venous thromboembolism among women with...

    Show More

    Paragraph 2 of the article begins, "Combined oral contraceptives are the mainstay treatment for PCOS." According to the 2009 Compendium of Pharmaceuticals and Specialities, estrogen-progestin birth control pills are indicated for contraception control and for the prevention of pregnancy. PCOS is not an approved indication for the BCP. Bird et al found a 2 fold increased risk of venous thromboembolism among women with PCOS taking combined oral contraceptives. It would seem wise not to prescribe the BCP to a woman with PCOS unless she is seeking contraception.

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
  • Posted on: (12 February 2013)
    Page navigation anchor for PCOS- at higher risk for thromboembolism
    PCOS- at higher risk for thromboembolism
    • dhastagir s Sheriff, Professor

    Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder that is characterized by hyperandrogenism and chronic anovulation, affecting about 5% of premenopausal women (1,2). This syndrome is an important condition associated with risk factors for stroke and coronary artery diseases, including hypertension, insulin resistance, high serum triglyceride levels, and low HDL cholesterol levels (3-6). Althoug...

    Show More

    Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder that is characterized by hyperandrogenism and chronic anovulation, affecting about 5% of premenopausal women (1,2). This syndrome is an important condition associated with risk factors for stroke and coronary artery diseases, including hypertension, insulin resistance, high serum triglyceride levels, and low HDL cholesterol levels (3-6). Although PCOS is associated with risk factors for cerebrovascular disease, the available evidence does not demonstrate increased stroke mortality, and it has been suggested that some protective mechanisms must be operating for these women (7,8).

    There are many studies which showed hemodynamic changes in the pelvic vessels and aorta in patients with PCOS (1,7,9,10). The present study confirms higher risk for venous thromboembolism cautioning the physicans about prescribing oral contraceptives to PCOS patients.

    References

    1. Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:742-6

    2. Franks S. Polycystic ovary syndrome. N Eng J Med 1995;333:853-61

    3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800

    4. Wild RA, Painter RC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985; 61:946-51

    5. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607

    6. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986; 112:432-7

    7. Lakhani K, Constantinovici N, Purcell WM, Fernando R, Hardiman P. Internal carotid artery haemodynamics in women with polycystic ovaries. Clin Sci 2000; 98:661-5

    8. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51:581-6

    9. Battaglia C, Artini PG, D'Ambrogio G, Allesandro D, Genazzani AD, Genazzani AR. The role of colour Doppler imaging in the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol 1995; 172:108-13

    10. Prelevic GM, Beljic T, Balint-Peric L, Ginsburg J. Cardiac flow velocity in women with the polycystic ovary syndrome. Clin Endocrinol 1995;43:677- 81

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 185 (2)
CMAJ
Vol. 185, Issue 2
5 Feb 2013
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis
Steven T. Bird, Abraham G. Hartzema, James M. Brophy, Mahyar Etminan, Joseph A.C. Delaney
CMAJ Feb 2013, 185 (2) E115-E120; DOI: 10.1503/cmaj.120677

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis
Steven T. Bird, Abraham G. Hartzema, James M. Brophy, Mahyar Etminan, Joseph A.C. Delaney
CMAJ Feb 2013, 185 (2) E115-E120; DOI: 10.1503/cmaj.120677
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and methods
    • Results
    • Interpretation
    • Acknowledgement
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights
  • PubMed
  • Google Scholar

Cited By...

  • Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential
  • Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
  • The polycystic ovary syndrome: a position statement from the European Society of Endocrinology
  • Exposure to combined oral contraceptives and risk of venous thromboembolism: a protocol for nested case-control studies using the QResearch and the CPRD databases
  • Risk of acute kidney injury associated with the use of fluoroquinolones
  • Google Scholar

More in this TOC Section

  • Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19–related deaths among people with multimorbidity: a cohort study
  • Association between virtual primary care and emergency department use during the first year of the COVID-19 pandemic in Ontario, Canada
  • Survival and health care costs after inpatient elective surgery: comparison of patients with and without chronic obstructive pulmonary disease
Show more Research

Similar Articles

Collections

  • Topics
    • Venous disease

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire